Mirella Mashiach
About Mirella Mashiach
As a veteran of the Bio industry, I've managed, funded, and headed dozens of strategic partnerships and investments. Through this experience, I saw many of the limitations of biotech drug development: the focus on only discrete pieces of the puzzle because of inability to understand whole biological systems, and how this limits our ability to create effective therapies; the lengthy and expensive drug development process, that ends in a binary failure/success (mostly failure); and the adverse impact on patients, who are left with either no treatment options or ones with limited efficacy and safety profiles. Now, as a co-founder of Output Biosciences (YC S21), I'm tackling these limitations and taking on a challenge in the next phase for biology and human health - we're creating Biologically-Aware Generative AI and building Large Biological Models that can understand entire complex biological system and generate breakthrough therapies. I am a former senior Pharma executive and biotech investor. I am also a founding partner of Mesia Ventures, a Bio startup studio. Prior to that, I was the Managing Director of the corporate venture fund at Teva Pharmaceuticals and its VP of BD and Strategy. Earlier, I was an attorney at Dentons, where I focused on corporate, commercial and intellectual property deals in life sciences. Building a startup from scratch, founding a startup studio, serving as an LP in VCs, sitting on startup boards, fostering alliances with partners from Academia to established companies, and providing legal counsel to private and public companies, have afforded me an unparalleled outlook on company building, investments and venture management. Come join us at Output Biosciences as we're building a team of talented and curious individuals who are committed to making a tangible impact on people's lives!